Table 3.
Total protein, defensins, cytokines, and chemokines for pregnant vs. non-pregnant women after log10 transformation.
| Mediatora | Percentage of subjects with levels below LODa (n=105) | Pregnant (n=70) | Non-pregnant (n=35) | FDR adjusted p-value |
|---|---|---|---|---|
| Total Protein (μg/ml) | 2 | 3.1 (1.4–3.7) | 3.1 (2.1–3.7) | 0.743 |
|
| ||||
| Alpha and Beta Defensins
| ||||
| HNP 1–3 (pg/ml) | 38 | 4.7 (4.1–6) | 4.6 (4.2–5.7) | 0.697 |
|
| ||||
| HBD-1 (pg/ml) | 42 | 3.2 (2.5–4.3) | 3.2 (2.5–4.3) | 0.543 |
|
| ||||
| HBD-2 (pg/ml) | 17 | 3.1 (2.4–5.3) | 4.2 (2.4–5.3) | <0.001c |
|
| ||||
| HBD-3 n (%)b | 58 | <0.001c | ||
| Detectable (>250 pg/ml) | 11 (16) | 33 (94) | ||
| Undetectable (≤250 pg/ml) | 59 (84) | 2 (6) | ||
|
| ||||
| Pro-Inflammatory Mediators
| ||||
| IL-1α (pg/ml) | 5 | 2.5 (0.5–4) | 1.9 (0.5–4) | 0.017c |
|
| ||||
| IL-1β (pg/ml) | 12 | 1.2 (−0.4–3.3) | 0.4 (−0.4–2.3) | 0.012c |
|
| ||||
| IL-6 (pg/ml) | 0 | 0.3 (−1.2–2.5) | 0.02 (−1.0–1.2) | 0.062 |
|
| ||||
| IL-8 (pg/ml) | 0 | 3.2 (1.2–4.0) | 2.5 (−0.4–4.0) | 0.007c |
|
| ||||
| IFN- α2, n (%)b | 91 | 0.480 | ||
| Detectable (>24.5 pg/ml) | 6 (9) | 3 (9) | ||
| Undetectable (≤24.5 pg/ml) | 64 (91) | 32 (91) | ||
|
| ||||
| MIP-1α, n (%)b | 73 | 0.459 | ||
| Detectable (>3.5 pg/ml) | 17 (24) | 11 (31) | ||
| Undetectable (≤3.5 pg/ml) | 53 (76) | 24 (69) | ||
|
| ||||
| MIP-1 β, n (%)b | 89 | 0.747 | ||
| Detectable (>4.5 pg/ml) | 9 (13) | 3 (9) | ||
| Undetectable (≤4.5 pg/ml) | 61(87) | 32 (91) | ||
|
| ||||
| RANTES n (%)b | 49 | |||
| Detectable (>2 pg/ml) | 43 (59) | 11 (31) | 0.002c | |
| Undetectable (≤2 pg/ml) | 27 (41) | 24 (69) | ||
|
| ||||
| Anti-Inflammatory Mediators
| ||||
| IL-1ra (pg/ml) | 1 | 5.1 (2.8–5.7) | 4.0 (0.5–5.6) | 0.006c |
|
| ||||
| SLPI (pg/ml) | 21 | 5.3 (4.4–6.3) | 5.7 (4.4–6.3) | 0.447 |
a
Limit of detection
b
Median (range) reported except for HBD-3, IFN-α2, MIP-1α, MIP-1β and RANTES which were dichotomized around the limit of detection.
c
p<0.05 considered statistically significant